clinical development is bremelanotide for treating female sexual dysfunction (FSD). In addition, they have drug candidates or development programs for obesity, erectile dysfunction, pulmonary diseases, cardiovascular diseases, and inflammatory diseases. Their current focus is on the design and development of receptor-selective melanocortin agonists for inflammation and autoimmune conditions, with a focus on ocular diseases. Their therapeutics work by activating endogenous melanocortin pathways to resolve damaging inflammation and allow affected tissues time to heal. Research has shown melanocortin agonists can prevent and reverse inflammation in disease models, including in the eyes and intestine—two of their targeted areas.